Skip to main content

Table 9 Differences in the approach to a second line treatment of CSU in physicians who do and do not follow the guidelines

From: Management of chronic spontaneous urticaria: a worldwide perspective

Treatment

Compared groups

n

% (n) of physicians, who follow the guidelines

% (n) of physicians, who don’t follow the guidelines

X2

p

First-generation H1-antihistamines

Administer

156

13.1 (136)

22.7 (20)

6.297

0.012

No

970

86.9 (902)

77.3 (68)

Second-generation H1-antihistamines at standard dose

Administer

127

11.3 (117)

11.4 (10)

0.001

0.979

No

999

88.7 (921)

88.6 (78)

Updosed second-generation H1-antihistamines

Administer

651

58.8 (610)

46.6 (41)

4.931

0.026

No

475

41.2 (428)

53.4 (47)

H2-antihistamines (e.g. famotidine or ranitidine)

Administer

308

27.1 (281)

30.7 (27)

0.532

0.466

No

818

72.9 (757)

69.3 (61)

Ciclosporin

Administer

76

6.8 (71)

5.7 (5)

0.173

0.678

No

1050

93.2 (967)

94.3 (83)

Omalizumab

Administer

163

14.5 (150)

14.8 (13)

0.007

0.934

No

963

85.5 (888)

85.2 (75)

Montelukast

Administer

391

35.5 (368)

26.1 (23)

3.106

0.078

No

735

64.5 (670)

73.9 (65)

Dapsone

Administer

39

3.2 (33)

6.8 (6)

3.213

0.073

No

1087

96.8 (1005)

93.2 (82)

Systemic corticosteroids (for less than 10 days)

Administer

265

23.8 (247)

20.5 (18)

0.503

0.478

No

861

76.2 (791)

79.5 (70)

Systemic corticosteroids (for more than 10 days in a row)

Administer

89

7.4 (77)

13.6 (12)

4.309

0.038

No

1037

92.6 (961)

86.4 (76)

Tricyclic antidepressants (e.g. doxepin)

Administer

137

11.6 (120)

19.3 (17)

4.568

0.033

No

989

88.4 (918)

80.7 (71)

  1. Values marked in bold indicate a statistically significant difference (p < 0.05)